XBiotech Inc. (NASDAQ:XBIT) Scheduled to Post Quarterly Earnings on Monday
XBiotech Inc. (NASDAQ:XBIT) will be announcing its earnings results before the market opens on Monday, August 14th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Shares of XBiotech Inc. (NASDAQ XBIT) opened at 4.39 on Monday. XBiotech Inc. has a 52-week low of $2.77 and a 52-week high of $20.18. The stock’s market capitalization is $154.92 million. The stock’s 50 day moving average is $4.82 and its 200 day moving average is $10.42.
COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/xbiotech-inc-nasdaqxbit-scheduled-to-post-quarterly-earnings-on-monday.html.
A number of research firms recently weighed in on XBIT. Noble Financial reaffirmed a “hold” rating and set a $13.00 price target on shares of XBiotech in a report on Friday, April 21st. Stifel Nicolaus raised shares of XBiotech from a “hold” rating to a “buy” rating in a report on Saturday, June 3rd. Zacks Investment Research raised shares of XBiotech from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Saturday, May 20th. Finally, ValuEngine lowered shares of XBiotech from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th.
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.
Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.